» Articles » PMID: 38434765

Regulation of Nrf2/Keap1 Signaling Pathway in Cancer Drug Resistance by Galectin-1: Cellular and Molecular Implications

Overview
Date 2024 Mar 4
PMID 38434765
Authors
Affiliations
Soon will be listed here.
Abstract

Oxidative stress is characterized by the deregulation of the redox state in the cells, which plays a role in the initiation of various types of cancers. The activity of galectin-1 (Gal-1) depends on the cell redox state and the redox state of the microenvironment. Gal-1 expression has been related to many different tumor types, as it plays important roles in several processes involved in cancer progression, such as apoptosis, cell migration, adhesion, and immune response. The erythroid-2-related factor 2 (Nrf2)/Kelch-like ECH-associated protein 1 (Keap1) signaling pathway is a crucial mechanism involved in both cell survival and cell defense against oxidative stress. In this review, we delve into the cellular and molecular roles played by Gal-1 in the context of oxidative stress onset in cancer cells, particularly focusing on its involvement in activating the Nrf2/Keap1 signaling pathway. The emerging evidence concerning the anti-apoptotic effect of Gal-1, together with its ability to sustain the activation of the Nrf2 pathway in counteracting oxidative stress, supports the role of Gal-1 in the promotion of tumor cells proliferation, immuno-suppression, and anti-tumor drug resistance, thus highlighting that the inhibition of Gal-1 emerges as a potential strategy for the restraint and regression of tumor progression. Overall, a deeper understanding of the multi-functionality and disease-specific expression profiling of Gal-1 will be crucial for the design and development of novel Gal-1 inhibitors as anticancer agents. Excitingly, although it is still understudied, the ever-growing knowledge of the sophisticated interplay between Gal-1 and Nrf2/Keap1 will enable researchers to gain valuable insights into the underlying causes of carcinogenesis and metastasis.

Citing Articles

The multifaceted perspectives on the regulation of lncRNAs in hepatocellular carcinoma ferroptosis: from bench-to-bedside.

Jin X, Huang C, Tian Y Clin Exp Med. 2024; 24(1):146.

PMID: 38960924 PMC: 11222271. DOI: 10.1007/s10238-024-01418-9.

References
1.
Gall Troselj K, Tomljanovic M, Jaganjac M, Glavan T, cipak Gasparovic A, Milkovic L . Oxidative Stress and Cancer Heterogeneity Orchestrate NRF2 Roles Relevant for Therapy Response. Molecules. 2022; 27(5). PMC: 8912061. DOI: 10.3390/molecules27051468. View

2.
Tinari N, Kuwabara I, Huflejt M, Shen P, Iacobelli S, Liu F . Glycoprotein 90K/MAC-2BP interacts with galectin-1 and mediates galectin-1-induced cell aggregation. Int J Cancer. 2001; 91(2):167-72. DOI: 10.1002/1097-0215(200002)9999:9999<::aid-ijc1022>3.3.co;2-q. View

3.
Cuadrado A, Manda G, Hassan A, Alcaraz M, Barbas C, Daiber A . Transcription Factor NRF2 as a Therapeutic Target for Chronic Diseases: A Systems Medicine Approach. Pharmacol Rev. 2018; 70(2):348-383. DOI: 10.1124/pr.117.014753. View

4.
Weng I, Chen H, Lo T, Lin W, Chen H, Hsu D . Cytosolic galectin-3 and -8 regulate antibacterial autophagy through differential recognition of host glycans on damaged phagosomes. Glycobiology. 2018; 28(6):392-405. DOI: 10.1093/glycob/cwy017. View

5.
Zucchetti M, Bonezzi K, Frapolli R, Sala F, Borsotti P, Zangarini M . Pharmacokinetics and antineoplastic activity of galectin-1-targeting OTX008 in combination with sunitinib. Cancer Chemother Pharmacol. 2013; 72(4):879-87. DOI: 10.1007/s00280-013-2270-2. View